Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
Same author

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Mayo Clinic Systematic Management and Risk-Adapted Therapy for Lymphoid Malignancies (lySMART) Consensus Guidelines 2026.

Mayo Clinic proceedings·2026
Same author

Proteomic profiling revealed unique disease biology associated with 1q abnormalities in multiple myeloma.

NPJ precision oncology·2026
Same author

A single next generation sequencing assay for detection of driver mutations, rearrangements and copy number abnormalities in plasma cell dyscrasias.

Blood cancer journal·2026
Same author

Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma.

Blood cancer discovery·2026
Same author

Genomic Proximity Mapping for Identification of Chromosomal Aberrations in Multiple Myeloma.

American journal of hematology·2026

Related Experiment Video

Updated: Mar 9, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K

Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity.

Sinto Sebastian1, Yuan X Zhu1, Esteban Braggio1

  • 1Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ.

Blood
|December 29, 2016
PubMed
Summary

Lenalidomide treats multiple myeloma by increasing hydrogen peroxide (H2O2) levels, which causes cell death. This mechanism involves inhibiting thioredoxin reductase (TrxR) and depends on the cereblon (CRBN) protein.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K

Related Experiment Videos

Last Updated: Mar 9, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Lenalidomide, an immunomodulatory drug (IMiD), is effective in multiple myeloma (MM).
  • The precise molecular mechanisms of lenalidomide's action and resistance, despite the requirement of cereblon (CRBN), are not fully understood.

Purpose of the Study:

  • To elucidate the molecular and biochemical mechanisms underlying lenalidomide's efficacy and resistance in multiple myeloma.
  • To investigate the role of hydrogen peroxide (H2O2) and thioredoxin reductase (TrxR) in lenalidomide's mechanism of action.

Main Methods:

  • Assessed IMiD activity by measuring intracellular H2O2 decomposition in MM cells.
  • Investigated the role of CRBN in lenalidomide's effects.
  • Examined the impact of lenalidomide on thioredoxin reductase (TrxR) and thioredoxin (Trx) activity.
  • Analyzed downstream effects including endoplasmic reticulum stress and BH3-only protein Bim activation.

Main Results:

  • IMiDs, including lenalidomide, primarily inhibit peroxidase-mediated H2O2 decomposition in MM cells.
  • MM cells with lower H2O2 decomposition capacity are more sensitive to lenalidomide-induced cytotoxicity.
  • Lenalidomide increases intracellular H2O2 by inhibiting TrxR in CRBN-expressing cells, leading to ER stress and Bim activation.
  • Direct TrxR or Trx inhibitors induce cytotoxicity independently of CRBN.

Conclusions:

  • Lenalidomide's efficacy in MM is mediated by CRBN-dependent inhibition of TrxR, leading to H2O2 accumulation and oxidative stress.
  • These findings may help identify patients who will benefit from IMiD therapy.
  • Direct TrxR or Trx inhibitors represent a potential therapeutic strategy for MM.